Trial Profile
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Probe Study With an Additional Open-Label Control Arm to Evaluate the Safety and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine in Subjects With Chronic Hepatitis C Virus Infection.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs V 520 (Primary) ; Diphtheria-tetanus vaccine
- Indications Diphtheria; HIV-1 infections; Tetanus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme Corp.
- 26 May 2010 Actual patient number (17) added as reported by ClinicalTrials.gov.
- 26 May 2010 Actual end date (MaY 2010) added as reported by ClinicalTrials.gov.
- 26 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.